LAMOND DAVID purchased 3.9% of their position (82.05K shares) of QUINCE THERAPEUTICS, INC. on the open market
Open‑market purchase worth $107.9K — a small addition. The strongest form of insider conviction signal.
P · 2 purchases
Filed: 8/31/2023ACC: 0001209191-23-047880
+82.05K
Net shares
Net buyer
$107.9K
Total acquired
2
Open market trades
2B · 0S
2
Total transactions
82.05K acquired
Non-Derivative Transactions2
Common Stock
Indirect
Shares
+41.03K
Price / share
$1.31
Trade value
$53.74K
% of position
2.0%
8/30/2023
2.10M→2.14M
Common Stock
Indirect
Shares
+41.03K
Price / share
$1.32
Trade value
$54.15K
% of position
1.9%
8/31/2023
2.14M→2.18M
Total
Net shares
+82.05K
Net value
$107.90K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 8/30/2023 | P · Purchase | +41.03K | $1.31 | $53.74K | 2.0% | 2.10M | 2.14M |
| Common Stock Indirect | 8/31/2023 | P · Purchase | +41.03K | $1.32 | $54.15K | 1.9% | 2.14M | 2.18M |
| Total | +82.05K | $107.90K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)2
Common Stock
DirectShares owned301.83K
Common Stock
IndirectShares owned1.73M
Total
301.83K direct·1.73M indirect2.04M
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 301.83K | Direct |
| Common Stock | 1.73M | Indirect |
| Total | 2.04M | 301.83K direct·1.73M indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported